A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

Trial Details

NCT ID
NCT07197554
Phase
PHASE1
Sponsor
SEED Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • ST-01156
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Newport Beach, California, United States|33.61891,-117.92895
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biologi…
  • Has a metastatic or locally advanced and unresectable solid tumor.
  • Has at least 1 measurable lesion or evaluable disease per RECIST v1.1.
  • Has an ECOG performance status ≤ 2 at screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →